Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024GlobeNewsWire • 10/31/24
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying OpportunitySeeking Alpha • 10/25/24
Intellia Therapeutics, Inc. (NTLA) Call to Discuss NTLA-2002 Phase 2 Study Results TranscriptSeeking Alpha • 10/24/24
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?Benzinga • 10/24/24
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)GlobeNewsWire • 10/24/24
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall StreetThe Motley Fool • 10/17/24
2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall StreetThe Motley Fool • 10/09/24
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)GlobeNewsWire • 10/07/24
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific SessionsGlobeNewsWire • 10/01/24
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific MeetingGlobeNewsWire • 09/12/24
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 08/08/24